Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice

Journal of Sexual Medicine

Volumn 11, Issue 2, 2014, Pages 574-582

  Conaglen, Helen M ^a   Paul, Ryan G ^a   Yarndley, Tania ^b   Kamp, Jozef ^a   Elston, Marianne S ^a,b   Conaglen, John V ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAIKATO HOSPITAL   (New Zealand)

Author keywords

Hypogonadism; Testosterone Deficiency Syndrome; Testosterone Replacement; Testosterone Undecanoate Depot

Indexed keywords

HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PELLET; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTOSIS; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPOGONADISM; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN; PELLET EXTRUSION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; ANDROGEN THERAPY; BLOOD; DELAYED RELEASE FORMULATION; DRUG IMPLANT; HORMONE SUBSTITUTION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; REFERENCE VALUE; TESTOSTERONE DEFICIENCY SYNDROME; TESTOSTERONE UNDECANOATE DEPOT; VERY ELDERLY; YOUNG ADULT;

HYPOGONADISM; TESTOSTERONE DEFICIENCY SYNDROME; TESTOSTERONE REPLACEMENT; TESTOSTERONE UNDECANOATE DEPOT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; LONG-TERM CARE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES; RETROSPECTIVE STUDIES; TESTOSTERONE; YOUNG ADULT;

EID: 84907081676     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12401     Document Type: Article

References (41)

1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
2. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-4247.
3. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 2009;94:907-913.
4. Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf) 2007;67:853-862.
5. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: Systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013;10:245-284.
6. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-2575.
7. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-492.
8. Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJG, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 2010;7:2572-2582.
9. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med 2013;10:1612-1627.
10. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497-501.
11. Yassin AA, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: A series of case reports. J Sex Med 2006;3:727-735.
12. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: Real-world data from the testim registry in the United States (TRiUS). J Sex Med 2011;8:3204-3213.
13. Kaminetsky JC, Moclair B, Hemani M, Sand M. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med 2011;8:1186-1196.
14. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;71:216-222.
15. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 1997;47:311-316.
16. Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 2010;11:2095-2106.
17. Minnemann T, Schubert M, Hubler D, Gouni-Berthold I, Freude S, Schumann C, Oettel M, Ernst M, Mellinger U, Sommer F, Krone W, Jockenhovel F. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007;10:155-158.
18. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-5434.
19. Minnemann T, Schubert M, Freude S, Hubler D, Gouni-Berthold I, Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Comparison of a new long-acting testosterone undecanoate formulation vs. testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008;31:718-723.
20. Jockenhovel F, Minnemann T, Schubert M, Freude S, Hubler D, Schumann C, Christoph A, Ernst M. Comparison of long-acting testosterone undecanoate formulation vs. testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160:815-819.
21. Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: A critical appraisal. Clin Interv Aging 2007;2:577-590.
22. Yassin AA, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013;3:73-83.
23. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009;30:1-9.
24. Moisey R, Swinburne J, Orme S. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1, 000mg IM-Nebido). Clin Endocrinol (Oxf) 2008;69:642-647.
25. von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002;23:419-425.
26. Gooren LJ, Bunck MC. Androgen replacement therapy: Present and future. Drugs 2004;64:1861-1891.
27. Saad F, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhel F, Behre HM, Gooren L, Nieschlag E. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 2007;9:291-297.
28. Haider A, Gooren LJ, Padungtod P, Saad F. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Andrologia 2010;42:349-355.
29. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:3844-3853.
30. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005;28:125-127.
31. Allan CA, McLachlan RI. Age-related changes in testosterone and the role of replacement therapy in older men. Clin Endocrinol (Oxf) 2004;60:653-670.
32. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
33. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1, 438 men. J Sex Med 2013;10:579-588.
34. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29-39.
35. Permpongkosol S, Tantirangsee N, Ratana-Olarn K. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: Effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010;7:3765-3774.
36. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-3503.
37. Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, Lenzi A, Migliaccio S. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 36 month controlled study. Aging Male 2012;15:96-102.
38. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: A Review. Curr Diabetes Rev 2012;8:131-143.
39. Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotrophic hypogonadism. J Sex Med 2011;8:3471-3478.
40. Sartorius G, Fennell C, Spasevska S, Turner L, Conway AJ, Handelsman DJ. Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate. Asian J Androl 2010;12:227-233.
41. Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, Handelsman DJ. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf) 2010;73:102-109.